home / stock / nonof / nonof news


NONOF News and Press, Novo-Nordisk A/S From 04/16/24

Stock Information

Company Name: Novo-Nordisk A/S
Stock Symbol: NONOF
Market: OTC
Website: novonordisk.com

Menu

NONOF NONOF Quote NONOF Short NONOF News NONOF Articles NONOF Message Board
Get NONOF Alerts

News, Short Squeeze, Breakout and More Instantly...

NONOF - VGK Vs. QQQ: How Europe's 'GRANOLAS' Could Outperform The US 'Magnificent 7'

2024-04-16 14:16:55 ET Summary Just as the "Magnificent 7" stocks lead returns and headlines in US markets, an 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. Here I run a head-to-head comparison using the Magnificent 7 as a proxy for the Invesco QQQ ET...

NONOF - GLP-1s benefit Parkinson's: Barclays sees implications across biopharma

2024-04-12 12:02:53 ET More on AbbVie, Biogen, etc. AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% Novo Nordisk: The Moat Won't Last Forever AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision No link between weight...

NONOF - No link between weight loss drugs and suicidal thoughts, EU regulator concludes

2024-04-12 07:05:43 ET More on Eli Lilly, Novo Nordisk, etc. Novo Nordisk: The Moat Won't Last Forever Eli Lilly: Three Threats To Its Huge Rally Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data Roche, Eli Lilly gain ...

NONOF - ClearBridge International Growth ADR Strategy Q1 2024 Commentary

2024-04-10 12:30:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We believe internation...

NONOF - Ginkgo Bioworks expands R&D tie-up with Novo Nordisk

2024-04-10 07:34:44 ET More on Ginkgo Bioworks Ginkgo Bioworks: Multiple Red Flags Ginkgo Bioworks: More Awful Revenue Guidance Ginkgo Bioworks Holdings, Inc. 2023 Q4 - Results - Earnings Call Presentation Ginkgo Bioworks acquires cell therapy assets from Mod...

NONOF - Eli Lilly launches construction of $2.5B plant to meet obesity drug demand

2024-04-09 13:06:07 ET More on Eli Lilly Eli Lilly: Three Threats To Its Huge Rally Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets EMA to ...

NONOF - Novo Nordisk: The Moat Won't Last Forever

2024-04-09 11:30:10 ET Summary Today, we take a look at Novo Nordisk A/S, whose growth is being powered by Wegovy and Ozempic. The GLP-1 market is projected by some to grow to $100 billion by 2030 and Novo Nordisk is currently the preeminent player in this burgeoning space. Ho...

NONOF - Novo's Ozempic to face copycats as Chinese firm seeks approval for biosimilar

2024-04-03 07:01:03 ET More on Novo Nordisk Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified Novo Nordisk, A Very Healthy Pharma Stalwart CVS, Elevance Health to c...

NONOF - Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'

2024-03-31 06:22:14 ET Summary Omega Therapeutics is a biotech company focused on developing programmable epigenomic mRNA medicines to control gene manifestation. The company's platform has applications in various diseases, including hepatocellular carcinoma, non-small cell lung c...

NONOF - CVS, Elevance Health to cover Novo Nordisk's Wegovy: WSJ

2024-03-28 10:00:53 ET More on CVS, Elevance Health, etc. Elevance: A Healthy Dose Of Dividend Growth Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront CVS Health: Here Comes The Floor - Inherent Undervaluation Triggers Great Upside Potential ...

Previous 10 Next 10